Allogeneic hematopoietic cell transplantation (HCT) represents the only curative treatment modality for patients with hematological malignancies. Disease risk stratification in various hematological malignancies incorporates cytogenetic aberrations and novel molecular abnormalities to help discern those who are anticipated to have a more aggressive course. As a result, treatment algorithms have evolved that dictate offering front-line allogeneic HCT to eligible candidates. Periodic karyotypic analysis remains an important disease assessment tool coupled with engraftment chimerism analysis post-HCT. Comparison to pre-HCT karyotype allows for detection of early cytogenetic relapse or persistence of the malignant clone present at the time of allografting. Rarely, a novel karyotypic abnormality may be identified in the course of post-HCT assessment. Such incidental chromosomal changes pose a significant clinical challenge and a therapeutic dilemma given that they may indicate clonal evolution, laboratory error or an incidental finding of donor-derived constitutional chromosomal abnormalities. Here we present four allogeneic HCT recipients in whom donor-derived constitutional chromosomal aberrations were identified during post-transplant evaluation.
The patient population included those who underwent an allogeneic HCT at the Moffitt Cancer Center between 1 January 2004 and 31 December 2014 and those with constitutional chromosomal abnormalities following allogeneic HCT were identified. All recipients underwent periodic chimerism analysis at approximately 1, 3, 6 and 12 months after allogeneic HCT based on standard protocol. The baseline patient characteristics at allogeneic HCT are summarized (Table 1) . This study was conducted with approval from the Liberty IRB Institutional Review Board and in compliance with the Declaration of Helsinki. We identified four cases of donor-derived constitutional chromosomal abnormalities discovered after receiving an allogeneic HCT, summarized in Table 1 . The median ages of recipients and donors were 71 (range, 29-75) and 33 (range, 27-42) years, respectively. Indications for allogeneic HCT were myelodysplastic syndrome (refractory anemia with excess blasts-2: n = 2), acute myeloid leukemia (n = 1) and acute lymphoblastic leukemia (n = 1). All four cases received peripheral blood stem cell grafts from HLA-matched unrelated donors. Preparative regimens were either busulfan/fludarabine or fludarabine/melphalan. Two patients received myeloablative preparative regimens. Three of the four patients received tacrolimus/sirolimus as GVHD prophylaxis regimen.
We identified four different constitutional chromosomal changes. In all cases, chromosomal changes were present in all 20 metaphases. In one gender mismatch case, these chromosomal changes were identified as being of donor origin based on sex chromosome difference. In the remaining three cases, recipients and donors were gender matched, and these were deemed constitutional changes given they were not observed in preallogeneic HCT clones. These constitutional chromosomal changes were noted in the first bone marrow biopsy sample following allogeneic HCT at a median of +35 days (range, +29 to +46). A patient with T-cell ALL (case 1) relapsed at approximately 6 months after allografting with an extramedullary soft tissue mass in her neck/shoulder area and is currently being treated with involved field radiation therapy.
One patient (case 3) relapsed with AML at 12 months after allogeneic HCT and received salvage chemotherapy. At the time of relapse, a minority of cells (2 out of the 20 metaphases) showed normal cytogenetics. After second remission was achieved, cytogenetics reverted to the same constitutional chromosomal changes of presumed donor origin. Two patients developed grade 2 gut GVHD and one patient had Epstein-Barr virus reactivation and Norovirus infection. It is unknown whether presumed chromosomal changes have any increased risk for GVHD or infections.
A systematic literature search was conducted using Medline/ PubMed for published studies through the peer-review process through 1 April 2015. The following combination of search terms was used: [allogeneic transplantation] AND [constitutional chromosomal abnormalities] OR [constitutional chromosomal rearrangements]. These searches were supplemented with a thorough review of references from those identified. Donor-derived constitutional chromosomal abnormalities after allogeneic HCT appear to be rare ( Table 2 ). All of our four cases had different constitutional chromosomal abnormalities of presumed donor origin, and none of them had been reported in the transplant literature to the best of our knowledge. All four cases were found to have the donor-derived constitutional chromosomal changes when first bone marrow biopsy was performed after allogeneic HCT (median day +35), and the karyotypic changes were present in all 20 metaphases. All cases achieved stable engraftment after allogeneic HCT. Although two of the four cases relapsed after an allograft, the association between the presence of constitutional chromosomal abnormalities and risk of malignancy relapse remains unclear.
Periodic cytogenetic evaluation of bone marrow after allogeneic HCT is performed routinely to assess disease status and to evaluate engraftment. Karyotypic analysis may signal early disease recurrence, persistent underlying hematological malignancies or clonal evolution. If known cytogenetic abnormalities of the underlying disease disappear after allogeneic HCT, the original disease clone is assumed to be eradicated. When new chromosomal changes are seen in all metaphases after allografting, laboratory error or constitutional chromosomal changes of donor origin should be considered in the differential. The latter requires careful evaluation of all documented chromosomal changes, including preallograft samples.
The limitations of our study include the small number of recipients with donor-derived constitutional chromosomal abnormalities, single-center review and unavailability of unrelated nonmalignant donor peripheral blood cells (T-cells cultured in PHAcontaining medium) or other benign tissues to confirm the germline status of the constitutional changes detected. In three gendermatched cases, the nature of constitutionality was assumed based on the absence of these chromosomal abnormalities in recipients' pre-HCT cytogenetic analysis, the universal presence of these chromosomal changes in post-HCT donor samples and stability of these chromosomal changes over time.
Balanced structural chromosomal abnormalities can be found in 0.2% of individuals generally manifesting a normal phenotype. Donor-derived constitutional chromosomal abnormalities previously reported include: inversion 9, trisomy 8, X chromosome deletion, and Robertsonian translocations. Pericentric inversion of chromosome 9 [inv(9)(p11-12q13)] occurs in approximately 3.57% of Blacks and 0.73-0.9% of Caucasians.
1 This is typically considered as a normal variant. An earlier report indicated that the constitutional inv (9) may be associated with delayed engraftment; 2 however, a subsequent study did not corroborate this finding.
3 Trisomy 8, either as a sole abnormality or in combination with other cytogenetic abnormalities, has been shown to occur in multiple hematological malignancies. Constitutional trisomy 8 has been described in subjects with normal phenotype and is known as trisomy 8 mosaicism. 4, 5 Robertsonian translocations are considered to be relatively common constitutional cytogenetic abnormalities involving the acrocentric chromosomes 13, 14, 15 (D group chromosomes), 21 and 22 (G group chromosomes). 6 The reported incidence of inherited Robertsonian translocations is 1 in 1000 newborns. In addition, acquired Robertsonian translocations may be found in hematological disorders at a higher frequency of 1 in 300-400. 7 Graze et al. 8 reported a case of phenotypically normal donor with a t (18;22) constitutional chromosome translocation. There was also another case of Robertsonian constitutional translocation noted from a donor (sister) with t(14;15) in a male recipient with CML. 9 Storb et al. 10 reported an allogeneic HCT from a donor with Down's syndrome (which was known prior to allogeneic HCT). Trisomy 21 was noted after the transplant with mixed chimerism but day +70 peripheral blood counts and marrow cellularity declined, and the patient received second allograft from a different donor. 10 Utilization of a donor with Down's syndrome appears extremely rare especially in the era when world-wide donor registries are available and alternative donor options are expanding.
None of the four different presumed donor-derived constitutional chromosomal abnormalities after allogeneic HCT shown in this paper have been previously reported in the allogeneic transplant literature. One case showed 45, XX, der(13;14)(q10;q10) in all 20 metaphases, which is consistent with a balanced Robertsonian translocation of donor origin. Robertsonian translocation between chromosomes 13 and 14 is the most common and D/D group translocation comprising 75% of all Robertsonian translocations. 11 Robertsonian translocation of chromosomes 13 and 14 may carry reproductive risks. 11 Only a limited number of cases have been reported in leukemias with this specific Abbreviations: AUC = area under the curve; BM = bone marrow; Bu = busulfan; F = female; Flu = fludarabine; HCT = hematopoietic cell transplantation; M = male; MDS = myelodysplastic syndrome; Mel = melphalan; MTX = methotrexate; MUD = matched-unrelated donor; RAEB-2 = refractory anemia with excess blasts-2; SIR = sirolimus; TAC = tacrolimus. Presumed constitutional chromosomal abnormalities are highlighted in bold.
a At pretransplant work-up; however, at diagnosis had 47,XY,+8 [6] translocation, 12 and whether it has any pathological role in leukemogenesis remains to be determined. The other abnormalities, t(11;15)(q13;q24), inv(12)(q13q22), t(3;5)(q12;q22) and t(3;5) (q21;q31), do not appear to have any prior reports in the published leukemia literature, based on our exhaustive search.
The possible association between the use of G-CSF and identification of donor-derived constitutional chromosomal abnormalities after allogeneic HCT was also considered. Although it is possible that constitutional chromosomal abnormalities may be under-reported, chromosomal alterations remain rare despite routine post-HCT karyotyping, and there appears to be no increased incidence in recent years when the large majority of adult allogeneic HCTs have been performed using G-CSFmobilized PBSC grafts.
Identification of chromosomal changes after allogeneic HCT requires careful evaluation to determine the cell of origin of such abnormalities to discern disease relapse or evolution of malignant clones. Constitutional chromosomal abnormalities of donor origin are rare and their association with relapse risk remains to be determined. We recommend considering concerted and collaborative efforts to develop a comprehensive database to evaluate donor-derived constitutional chromosomal abnormalities after allogeneic HCT by donor registries. Increasing transplant physicians' awareness and education on non-malignant chromosomal rearrangement including Robertsonian translocations and thorough reviews of cytogenetic changes are essential to accurately diagnose donor-derived constitutional abnormalities after allogeneic transplantation and optimize post-transplant management.
